Skip to content

Study · Randomized controlled trial · n = 320 · 2002

3 results

Adjuvant endocrine treatment (goserelin vs tamoxifen) in pre-menopausal patients with operable node positive stage II breast cancer. A prospective randomized national multicenter study.

Söreide JA, Varhaug JE, Fjösne HE, Erikstein B, Jacobsen AB, Skovlund E, Kvinnsland S

European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology1 Aug 2002Cited by 16 (Europe PMC)

PMID12217302 (opens in a new tab)DOI10.1053/ejso.2002.1280 (opens in a new tab)PepBankPUB-12217302
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with node-positive breast cancer, goserelin and tamoxifen showed no difference in time to first recurrence.

    In plain wordsIn premenopausal women with breast cancer, goserelin and tamoxifen showed no difference in time to first recurrence.

    Peptide
    Goserelin
    Outcome
    No significant changeTime to first recurrence
    Study

    n = 320

    Comparator
    tamoxifen
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · two yearsAs given in this study (human).

    Source sentences

    Summary
    No differences in time to first recurrence or overall survival were observed between treatment groups.
    1 context sentence
    Summary · context
    Between January 1989 and July 1994, 320 patients with node positive (pN(+)) and hormone receptor positive or receptor status unknown tumors were included and randomized in a national multicenter study to receive either tamoxifen or goserelin as adjuvant treatment for two years.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with node-positive breast cancer, overall survival did not differ between goserelin and tamoxifen.

    In plain wordsIn premenopausal women with breast cancer, survival did not differ between goserelin and tamoxifen.

    Peptide
    Goserelin
    Outcome
    No significant changeOverall survival
    Study

    n = 320

    Comparator
    tamoxifen
    Outcome group
    Mortality · Cancer
    Studied dose
    Dose not stated · two yearsAs given in this study (human).

    Source sentences

    Summary
    No differences in time to first recurrence or overall survival were observed between treatment groups.
    1 context sentence
    Summary · context
    Between January 1989 and July 1994, 320 patients with node positive (pN(+)) and hormone receptor positive or receptor status unknown tumors were included and randomized in a national multicenter study to receive either tamoxifen or goserelin as adjuvant treatment for two years.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In premenopausal women with breast cancer, second breast cancer proportions were similar with goserelin and tamoxifen.

    In plain wordsIn premenopausal women with breast cancer, second breast cancer proportions were similar with goserelin and tamoxifen.

    Peptide
    Goserelin
    Outcome
    Not applicableSecond breast cancer
    Study

    n = 320

    Comparator
    tamoxifen
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · two yearsAs given in this study (human).

    Source sentences

    Summary
    Proportions of patients in each group having a second breast cancer were also similar.
    1 context sentence
    Summary · context
    Between January 1989 and July 1994, 320 patients with node positive (pN(+)) and hormone receptor positive or receptor status unknown tumors were included and randomized in a national multicenter study to receive either tamoxifen or goserelin as adjuvant treatment for two years.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.